

Biliary Tract Cancers

ECOG-ACRIN EA2187 NCT04175912	Temp closed to accrual 3/31/21	A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
--	---	--

BioBanking

Brain

NRG BN007 NCT04396860	Temp Closed to Accrual 4/27/22	A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab vs. Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
NRG-BN011 NCT05095379		A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

Breast - Neoadjuvant

Alliance A011202 NCT01901094	Temp. Closed to Accrual 1/14/2022	A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
---	--	---

Breast - DCIS

AFT-25 COMET NCT02926911		Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
-------------------------------------	--	---

Breast - Adjuvant Triple Negative

BREAST - Adjuvant HR Positive

BREAST - Adjuvant HER2+

ECOG-ACRIN EA1181 NCT04266249		(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Alliance A011801 NCT04457596		The CompassHER2 Trials (COMprehensive use of Pathologic Repsonse ASSEssment to optimize Therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
DFCI 21-159 ATEMPT NCT04893109		A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab vs. Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT 2.0)

Breast - Adjuvant XRT

CCTG MA.39 NCT03488693		A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706 NCT03598257		A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer

Breast - Metastatic

NRG BR004 NCT03199885	Temp Closed to Accrual 4/29/22	A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
--------------------------	--------------------------------------	--

Breast - Locally Advanced/Metastatic HER2+/HR+

DFCI 20-347 ADEPT NCT04569747		A Single Arm Phase II Study of Adjuvant Endocrine Therapy, Subcutaneous Pertuzumab, and Trastuzumab Fixed-Dose Combination for Patients With Anatomic Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer
----------------------------------	--	--

ER+/HER2-

Triple Negative

DFCI 18-617 NCT# N/A		A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients With Early-Stage or Newly Diagnosed Metastatic Disease: The TNBC Registry
-------------------------	--	--

Longitudinal Study

DFCI 18-634 ELEVATE NCT03818087		ELEVATE: Improving Outcomes for Older Patients with Breast Cancer: A Longitudinal Cohort and Patient Engagement Study
------------------------------------	--	---

Radiation

NRG-BR007 NCT04852887		A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer
--------------------------	--	---

Children's Oncology Group Registry

APEC14B1 (Patient's 25 and Younger)		Project EveryChild: A Registry, Eligibility Screening, Biology and Outcome Registry
--	--	---

Colorectal

Alliance A021502 NCT02912559	DTL Required	Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Alliance A021703 NCT04094688		Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
NRG GI004 NCT02997228	DTL Required	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
NRG-GI005 NCT04068103		Phase II/III Study of Circulating tumor DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
SWOG S1922 NCT04205968		Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Gastroesophageal

EA2174 NCT03604991		A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
-----------------------	--	---

Genitourinary

ECOG EA8185 NCT04216290		Phase II Study of Bladder-Sparing Chemoradiation With MEDI4736 (durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)
----------------------------	--	---

Germ Cell

AGCT1531 NCT03067181 (Patients <50 years of age)		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532 NCT02585697 (Patients <= 45 years of age)		A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

GYN

NRG GY014 NCT03348631		A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
NRG GY019 NCT04095364		A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin /Maintenance Letrozole vs Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
DFCI 20-065 NCT04354454		Step into Support for Endurance and Strength
NRG GY012 NCT03660826	Temp. Closed to Accrual 2/22/2022	A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasterib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
NRG-GY018 NCT03914612		A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
NRG-GY023 NCT04739800		A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Head and Neck

NRG-HN009 NCT05050162		Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100mg/m ²) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40mg/m ²) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
--------------------------	--	---

Hodgkin Lymphoma

S1826 NCT03907488		A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vendotin(Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
----------------------	--	--

Leukemia - Untreated/Newly Diagnosed

Alliance A041701 NCT03701308	DTL Required Temp. closed to accrual 11/19/21	A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Alliance A041702 NCT03737981		A Randomized Phase III Trial of Ibrutinib Plus Obintuzumab versus Ibrutinib Plus Venetoclax and Obintuzumab in Untreated Older Patients (≥ 65) Years of Age) with Chronic Lymphocytic Leukemia (CLL)
DFCI 18-089 NCT03534323		A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Patients or Patients with Richter's Syndrome
DFCI 18-226 NCT03580928		A Phase 2 Study of Acalabrutinib, Venetoclax, and Obintuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia

Lung Cancer - Screening Adjuvant

Alliance A151216 (ALCHEMIST) NCT02194738		Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
--	--	--

Lung Cancer - Adjuvant

Alliance A081801 NCT04267848		Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
ECOG E4512 (ALCHEMIST) NCT 02201992		A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG 1827 NCT04155034		MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Lung Cancer - Genotyping

DFCI 19-523 NCT04166487		Pilot Study of Serial Plasma Genotyping to Guide the Adaptive Treatment of Advanced NSCLC Receiving First-Line Pembrolizumab
----------------------------	--	--

Lung Cancer - Unresectable

ECOG-ACRIN EA5181 NCT04092283		Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
----------------------------------	--	---

Lung Cancer - 1st Line Metastatic

ECOG-ACRIN EA5163 NCT03793179		INSIGNIA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Non-squamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis
----------------------------------	--	--

Lung Cancer - 2nd Line Metastatic

LUNGMAP NCT02154490		A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
SWOG 1900E NCT04625647		Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
SWOG S1800D NCT05096663		A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Lymphoma

Alliance A051701 NCT03984448	Temp closed to accrual 8/2/2021	Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MC/BCL2 Double-Hit and Double-Expressing Lymphomas
ECOG-ACRIN EA4181 NCT04115631		A Randomized 3 Arm Phase II Study Comparing 1) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 Years old with Untreated Mantle Cell Lymphoma
ANHL1931 NCT04759586		A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (Patients \geq 2 years of age)

MCGI

MCGI 2.0		The Maine Cancer Genomics Initiative (MCGI) 2.0: A Study of Oncology Clinician and Patient Experiences with Clinical Genomics in Northern New England
-----------------	--	---

Melanoma - Locally Advanced Metastatic

ECOG-ACRIN EA6141 NCT02339571		Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
--	--	--

Melanoma - Adjuvant

Merkel Cell

EA6174 NCT03712605		STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III Trial
-------------------------------	--	--

Multiple Tumor Types

ECOG-ACRIN EAY131 (MATCH) NCT02465060		Molecular Analysis for Therapy Choice (MATCH)
--	--	---

Myeloma

SWOG S1803 NCT04071457		Phase III Study of Daratumumab/HuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as PostAutologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)
AFT-41 NCT04009109		A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

Myeloma - Relapsed/Refractory

Prevention

Alliance A151804 NCT04242095		Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Alliance A221805 NCT04137107		Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Prostate

SWOG S1802 NCT03678025		Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
NRG-GU008 NCT04134260		Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

Rare Tumors

SWOG S1609 NCT02834013		DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
TAPUR NCT02693535		The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Renal

Alliance A031704 (PDIGREE) NCT03793166		PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGFTKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
---	--	--

Rhabdomyosarcoma

ARST1431 NCT02567435 (Patients \leq 40 years of age)		A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
--	--	--